Copyright Reports & Markets. All rights reserved.

Global Glucagon-like Peptide-1 Receptor Agonist Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Glucagon-like Peptide-1 Receptor Agonist Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Glucagon-like Peptide-1 Receptor Agonist Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Exenatide
    • 1.4.3 Liraglutide
    • 1.4.4 Lixisenatide
    • 1.4.5 Albiglutide
    • 1.4.6 Others
  • 1.5 Market by Application
    • 1.5.1 Global Glucagon-like Peptide-1 Receptor Agonist Market Share by Application: 2020 VS 2026
    • 1.5.2 Solid Tumors
    • 1.5.3 Blood-related Tumors
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends by Regions

  • 2.1 Glucagon-like Peptide-1 Receptor Agonist Market Perspective (2015-2026)
  • 2.2 Glucagon-like Peptide-1 Receptor Agonist Growth Trends by Regions
    • 2.2.1 Glucagon-like Peptide-1 Receptor Agonist Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Glucagon-like Peptide-1 Receptor Agonist Historic Market Share by Regions (2015-2020)
    • 2.2.3 Glucagon-like Peptide-1 Receptor Agonist Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Glucagon-like Peptide-1 Receptor Agonist Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Glucagon-like Peptide-1 Receptor Agonist Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Glucagon-like Peptide-1 Receptor Agonist Players by Market Size
    • 3.1.1 Global Top Glucagon-like Peptide-1 Receptor Agonist Players by Revenue (2015-2020)
    • 3.1.2 Global Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Glucagon-like Peptide-1 Receptor Agonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Glucagon-like Peptide-1 Receptor Agonist Market Concentration Ratio
    • 3.2.1 Global Glucagon-like Peptide-1 Receptor Agonist Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Glucagon-like Peptide-1 Receptor Agonist Revenue in 2019
  • 3.3 Glucagon-like Peptide-1 Receptor Agonist Key Players Head office and Area Served
  • 3.4 Key Players Glucagon-like Peptide-1 Receptor Agonist Product Solution and Service
  • 3.5 Date of Enter into Glucagon-like Peptide-1 Receptor Agonist Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Glucagon-like Peptide-1 Receptor Agonist Historic Market Size by Type (2015-2020)
  • 4.2 Global Glucagon-like Peptide-1 Receptor Agonist Forecasted Market Size by Type (2021-2026)

5 Glucagon-like Peptide-1 Receptor Agonist Breakdown Data by Application (2015-2026)

  • 5.1 Global Glucagon-like Peptide-1 Receptor Agonist Market Size by Application (2015-2020)
  • 5.2 Global Glucagon-like Peptide-1 Receptor Agonist Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Glucagon-like Peptide-1 Receptor Agonist Market Size (2015-2020)
  • 6.2 Glucagon-like Peptide-1 Receptor Agonist Key Players in North America (2019-2020)
  • 6.3 North America Glucagon-like Peptide-1 Receptor Agonist Market Size by Type (2015-2020)
  • 6.4 North America Glucagon-like Peptide-1 Receptor Agonist Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Glucagon-like Peptide-1 Receptor Agonist Market Size (2015-2020)
  • 7.2 Glucagon-like Peptide-1 Receptor Agonist Key Players in Europe (2019-2020)
  • 7.3 Europe Glucagon-like Peptide-1 Receptor Agonist Market Size by Type (2015-2020)
  • 7.4 Europe Glucagon-like Peptide-1 Receptor Agonist Market Size by Application (2015-2020)

8 China

  • 8.1 China Glucagon-like Peptide-1 Receptor Agonist Market Size (2015-2020)
  • 8.2 Glucagon-like Peptide-1 Receptor Agonist Key Players in China (2019-2020)
  • 8.3 China Glucagon-like Peptide-1 Receptor Agonist Market Size by Type (2015-2020)
  • 8.4 China Glucagon-like Peptide-1 Receptor Agonist Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Glucagon-like Peptide-1 Receptor Agonist Market Size (2015-2020)
  • 9.2 Glucagon-like Peptide-1 Receptor Agonist Key Players in Japan (2019-2020)
  • 9.3 Japan Glucagon-like Peptide-1 Receptor Agonist Market Size by Type (2015-2020)
  • 9.4 Japan Glucagon-like Peptide-1 Receptor Agonist Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Glucagon-like Peptide-1 Receptor Agonist Market Size (2015-2020)
  • 10.2 Glucagon-like Peptide-1 Receptor Agonist Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Glucagon-like Peptide-1 Receptor Agonist Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Glucagon-like Peptide-1 Receptor Agonist Market Size by Application (2015-2020)

11 India

  • 11.1 India Glucagon-like Peptide-1 Receptor Agonist Market Size (2015-2020)
  • 11.2 Glucagon-like Peptide-1 Receptor Agonist Key Players in India (2019-2020)
  • 11.3 India Glucagon-like Peptide-1 Receptor Agonist Market Size by Type (2015-2020)
  • 11.4 India Glucagon-like Peptide-1 Receptor Agonist Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Glucagon-like Peptide-1 Receptor Agonist Market Size (2015-2020)
  • 12.2 Glucagon-like Peptide-1 Receptor Agonist Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Glucagon-like Peptide-1 Receptor Agonist Market Size by Type (2015-2020)
  • 12.4 Central & South America Glucagon-like Peptide-1 Receptor Agonist Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 GSK
    • 13.1.1 GSK Company Details
    • 13.1.2 GSK Business Overview and Its Total Revenue
    • 13.1.3 GSK Glucagon-like Peptide-1 Receptor Agonist Introduction
    • 13.1.4 GSK Revenue in Glucagon-like Peptide-1 Receptor Agonist Business (2015-2020))
    • 13.1.5 GSK Recent Development
  • 13.2 Novo Nordisk
    • 13.2.1 Novo Nordisk Company Details
    • 13.2.2 Novo Nordisk Business Overview and Its Total Revenue
    • 13.2.3 Novo Nordisk Glucagon-like Peptide-1 Receptor Agonist Introduction
    • 13.2.4 Novo Nordisk Revenue in Glucagon-like Peptide-1 Receptor Agonist Business (2015-2020)
    • 13.2.5 Novo Nordisk Recent Development
  • 13.3 Lily
    • 13.3.1 Lily Company Details
    • 13.3.2 Lily Business Overview and Its Total Revenue
    • 13.3.3 Lily Glucagon-like Peptide-1 Receptor Agonist Introduction
    • 13.3.4 Lily Revenue in Glucagon-like Peptide-1 Receptor Agonist Business (2015-2020)
    • 13.3.5 Lily Recent Development
  • 13.4 Haosoh
    • 13.4.1 Haosoh Company Details
    • 13.4.2 Haosoh Business Overview and Its Total Revenue
    • 13.4.3 Haosoh Glucagon-like Peptide-1 Receptor Agonist Introduction
    • 13.4.4 Haosoh Revenue in Glucagon-like Peptide-1 Receptor Agonist Business (2015-2020)
    • 13.4.5 Haosoh Recent Development
  • 13.5 Sanofi
    • 13.5.1 Sanofi Company Details
    • 13.5.2 Sanofi Business Overview and Its Total Revenue
    • 13.5.3 Sanofi Glucagon-like Peptide-1 Receptor Agonist Introduction
    • 13.5.4 Sanofi Revenue in Glucagon-like Peptide-1 Receptor Agonist Business (2015-2020)
    • 13.5.5 Sanofi Recent Development
  • 13.6 AstraZeneca
    • 13.6.1 AstraZeneca Company Details
    • 13.6.2 AstraZeneca Business Overview and Its Total Revenue
    • 13.6.3 AstraZeneca Glucagon-like Peptide-1 Receptor Agonist Introduction
    • 13.6.4 AstraZeneca Revenue in Glucagon-like Peptide-1 Receptor Agonist Business (2015-2020)
    • 13.6.5 AstraZeneca Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global Glucagon-like Peptide-1 Receptor Agonist status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Glucagon-like Peptide-1 Receptor Agonist development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    GSK
    Novo Nordisk
    Lily
    Haosoh
    Sanofi
    AstraZeneca
    ...

    Market segment by Type, the product can be split into
    Exenatide
    Liraglutide
    Lixisenatide
    Albiglutide
    Others
    Market segment by Application, split into
    Solid Tumors
    Blood-related Tumors

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global Glucagon-like Peptide-1 Receptor Agonist status, future forecast, growth opportunity, key market and key players.
    To present the Glucagon-like Peptide-1 Receptor Agonist development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of Glucagon-like Peptide-1 Receptor Agonist are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now